Abeona Therapeutics Inc. $ABEO Shares Bought by Sei Investments Co.

Sei Investments Co. boosted its stake in Abeona Therapeutics Inc. (NASDAQ:ABEO) by 142.4% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 172,460 shares of the biopharmaceutical company’s stock after acquiring an additional 101,307 shares during the quarter. Sei Investments Co.’s holdings in Abeona Therapeutics were worth $773,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ABEO. Legal & General Group Plc purchased a new stake in shares of Abeona Therapeutics during the second quarter worth approximately $27,000. Russell Investments Group Ltd. acquired a new position in Abeona Therapeutics in the 3rd quarter valued at $37,000. Truvestments Capital LLC lifted its holdings in Abeona Therapeutics by 191.4% in the 4th quarter. Truvestments Capital LLC now owns 10,307 shares of the biopharmaceutical company’s stock valued at $54,000 after purchasing an additional 6,770 shares in the last quarter. SG Americas Securities LLC purchased a new position in Abeona Therapeutics in the 4th quarter valued at $57,000. Finally, Man Group plc acquired a new stake in Abeona Therapeutics during the 2nd quarter worth $67,000. Hedge funds and other institutional investors own 80.56% of the company’s stock.

Abeona Therapeutics Price Performance

NASDAQ:ABEO opened at $6.34 on Friday. Abeona Therapeutics Inc. has a one year low of $4.00 and a one year high of $7.65. The stock has a market cap of $361.32 million, a PE ratio of 6.54 and a beta of 1.35. The company has a debt-to-equity ratio of 0.03, a quick ratio of 5.70 and a current ratio of 5.89. The stock has a 50 day moving average price of $6.30 and a 200 day moving average price of $5.57.

Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.12). The business had revenue of $11.38 million during the quarter, compared to the consensus estimate of $12.24 million. Equities research analysts expect that Abeona Therapeutics Inc. will post -0.79 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ABEO has been the subject of a number of research reports. Weiss Ratings lowered shares of Abeona Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, August 3rd. Wall Street Zen raised shares of Abeona Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 1st. Finally, HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Abeona Therapeutics in a research report on Thursday, May 28th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $19.00.

Insiders Place Their Bets

In other news, Director Leila Alland sold 11,000 shares of Abeona Therapeutics stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $5.92, for a total transaction of $65,120.00. Following the transaction, the director owned 162,614 shares in the company, valued at $962,674.88. The trade was a 6.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Joseph Walter Vazzano sold 24,880 shares of the business’s stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $6.96, for a total transaction of $173,164.80. Following the transaction, the chief financial officer directly owned 493,557 shares in the company, valued at approximately $3,435,156.72. The trade was a 4.80% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 281,078 shares of company stock worth $1,709,923. 7.10% of the stock is currently owned by company insiders.

Abeona Therapeutics Profile

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.